Key result
LV myocardial work index predicts 6-month mortality in light-chain cardiac amyloidosis with ~0.81 AUC.
Why the study?
Decompensated heart failure causes high early mortality in advanced AL-CA, preventing delayed chemotherapy response, while LVMWI is a novel cardiac function parameter whose association with short-term outcomes needed evaluation.
Does left ventricular myocardial work index predict 6-month all-cause mortality in patients with light-chain cardiac amyloidosis?
Cohort (n=79)
No
Does left ventricular myocardial work index predict 6-month all-cause mortality in patients with light-chain cardiac amyloidosis?
Effect estimate: AUC 0.805 (95% CI 0.690-0.920)
p-value: p=<0.001
Left ventricular myocardial work index is a useful load-independent parameter for predicting short-term mortality in patients with light-chain cardiac amyloidosis, and its prognostic value is enhanced by D-dimer assessment.
Background: Reports show that the left ventricular myocardial work index (LVMWI) is a novel parameter for evaluating cardiac function. Decompensated heart failure leads to a high rate of early mortality in advanced patients with light-chain cardiac amyloidosis (AL-CA) and prevents them from a relatively delayed response to chemotherapy. This study aimed to assess the association of the LVMWI with short-term outcomes and to construct a simple model for risk stratification. Methods: A total of 79 patients with an initial diagnosis of AL-CA were included in this retrospective cohort study. LVMWI was calculated by integrating brachial artery cuff blood pressure and left ventricular longitudinal strain (LVLS). The short-term outcome was defined as 6-month all-cause mortality. Receiver operating characteristic (ROC), logistic regression, and Kaplan-Meier analysis were used in this study. Results: The median follow-up time was 21 months (3–36 months), and 23 (29%) patients died in the first 6 months. The time-dependent ROC and the area under the curve (AUC) showed that the LVMWI had the best predictive potential at the 6-month time point [AUC =0.805; 95% confidence interval (CI): 0.690–0.920]. A bivariate prognostic model based on the LVMWI was constructed, and D-dimer showed a synergistic effect with optimum predicted potential (AUC =0.877; 95% CI: 0.791–0.964). Kaplan-Meier analysis demonstrated that patients with two, one, and none of the variates beyond the cut-off value bore a different risk of 6-month all-cause mortality (accumulated mortality was 86%, 30%, 3%, respectively; log-rank, P<0.001). Multivariate nested logistic regression showed that the level of D-dimer provided an incremental prognostic value (Δχ2=10.3; P=0.001) to the value determined from New York Heart Association (NYHA) classification and the LVMWI. Conclusions: The LVMWI is associated with the short-term outcome of patients with AL-CA. The D-dimer test provides additional prognostic information for the LVMWI.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2022) conducted a cohort in light-chain cardiac amyloidosis (AL-CA) (n=79). Left ventricular myocardial work index (LVMWI) was evaluated on 6-month all-cause mortality (AUC 0.805, 95% CI 0.690-0.920, p=<0.001). Left ventricular myocardial work index demonstrated strong predictive potential for 6-month all-cause mortality (AUC 0.805) in patients with light-chain cardiac amyloidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: